Presentation at the DFSG 2022

We're so excited for exhibiting at the Diabetic Foot Study Group (DFSG) conference next week. Please be sure to visit us at booth no.11 where we will based during the conference. We welcome you to see our SteriPlas Cold Plasma medical device live in action.

We're also excited to announce that the Diabetes Team at Kettering General Hospital NHS Foundation Trust will have a poster presentation illustrating the strong antibacterial efficacy and healing qualities of the Adtec SteriPlas for diabetic foot ulcers.

The poster, "DGH EXPERIENCE OF USING COLD PLASMA MEDICAL DEVICE AS AN ADJUNCT THERAPY TO ANTIMICROBIALS IN TREATING CHRONIC NON HEALING INFECTED DIABETIC FOOT ULCERS" will be presented by Jemma Cruickshank on Saturday 17th September, 13:25 - 14:25.

See you all soon!


The ISHLT discusses the Cold Plasma Project

We’re ecstatic to see our Adtec SteriPlas continue to raise awareness in the LVAD community. A great interview between the ISHLT and Mr Thomas Schlöglhofer from the Medical University of Vienna discussing the benefits of our cold atmospheric plasma medical device for the treatment of LVAD Infections and their broad study being conducted.

Thomas has been an avid user of our medical device for some time now collecting remarkable results with his LVAD patients, documenting the strong benefits of our medical device including the significant reduction of infection rates coupled with full healing, reduction of readmittance and the stabilisation of LVAD systems all with the added benefit of no side effects.

We look forward to the completion of this study and the publishing of the data which will be discussed at the ISHLT 2023 conference next year. We will also be exhibiting at this conference and excited to meet more people from the LVAD community.

 

https://youtu.be/6-L0sgXLx9o


Antimicrobial (antibiotic) Resistance – the drugs won’t work !

Antimicrobial resistance (AMR) poses a significant global threat of far-reaching proportions. It is estimated that drug resistant infections contribute to nearly 5 million deaths every year and predicted to increase to over 10 million deaths every year.  WHO has declared that AMR is one of the top 10 global public health threats facing humanity.

(The worldwide total deaths from COVID is now just over 6 million and we all know how frightening it was before the vaccine was developed)

 

AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”. Without effective antimicrobials, the success of modern medicine in treating infections, including during major surgery and cancer chemotherapy, would be at increased risk. Chronic infections if left untreated could result in tissue damage, amputation, longer stays in hospitals, surgical interventions, or increased possibility of mortality. Patients who are infected with drug-resistant infections are more likely to develop complications and are up to three times more likely to die from the infection. Non-healing wounds in particular, are characterised by complex and mixed bacterial populations, often involving antibiotic-resistant bacteria as well as phenotypically tolerant bacteria in biofilm form. The biofilm factor is clearly of considerable clinical importance: it protects bacteria from antimicrobial agents leading to persistent and difficult to treat chronic infections, and it exacerbates the spread of antibiotic resistance. Surgical Site Infections are also linked to anti-microbial resistance.

 

SteriPlas cold plasma technology kills bacteria by a physical mode of action and bacteria are therefore unlikely to develop primary or secondary resistance, which we have documented from our clinical studies. SteriPlas cold plasma also kills antibiotic resistant bacteria (e.g. MRSA) and kills bacteria encased in biofilm which are typically up to 1000 times more resistant to antibiotics. SteriPlas has proven clinical efficacy in treating wound infections,  diabetic foot infections and surgical site infections in all clinical studies, all with the bonus of no side effects reported. 

 

SteriPlas cold plasma can be used to treat topical infections reserving antibiotics for severe systemic infections.

 

References

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext

https://www.worldometers.info/coronavirus/

https://www.who.int/health-topics/antimicrobial-resistance

https://healthfirsteurope.eu/wp-content/uploads/2020/11/A3A4-48pp-Booklet-Spreads-1.pdf

Bowler, P., Murphy, C. & Wolcott, R. Biofilm exacerbates antibiotic resistance: Is this a current oversight in antimicrobial stewardship?. Antimicrob Resist Infect Control 9, 162 (2020).


Taiwan Wound Therapy Society Conference, March 2022

 

Sharing some photos from last weekend at the Taiwan Wound Therapy Society conference.

Our medical distributor, SG Biomedical, had a productive weekend demonstrating our SteriPlas to doctors and nurses keen to learn about the benefits of cold plasma for the treatment of wounds, surgical site infections and medical dermatology. 

 

For more information about the Adtec SteriPlas and how to obtain this in the SE Asia region, please contact our distributor SG Biomedical for more information.


ToGCPiCPT

 

Congratulations to our Business Development Manager, Jeiram, for his published chapter in the “Textbook of Good Clinical Practice in Cold Plasma Therapy”. This prestigious book houses powerful material from esteemed authors in the cold plasma medicine field.

 

Jeiram’s chapter, “SteriPlas® and PlasmaTact®”, discusses the importance of Adtec Healthcare’s influence in the cold plasma medicine field from being the first company ever to conduct cold plasma clinical trials on wounds and to our modern day clinical efficacy in wounds, surgical site infections and medical dermatology skin conditions.

 

You can view this chapter here: https://doi.org/10.1007/978-3-030-87857-3_18

 

For more information about our cold plasma medical and non-medical devices, please contact us at info@adtecplasma.com

 


Our Cold Plasma Medical Device leads the way

Bacteria protected within biofilm are up to 1000x more resistant to antibiotics. This can complicate treatment options for wounds and surgical site infections but as it is an international form of therapy, it remains used throughout patient treatments despite it offering little to no help in healing problematic/stalled wounds and infections.

 

The cost burden associated to ongoing antibiotic therapy is significant as is the antimicrobial resistance rates that are ever growing. The World Health Organisation recognizes this and more hospitals are reaching out to alternative therapies to help curb the spending costs and antimicrobial resistance rates.

 

As the Adtec SteriPlas cold plasma has been shown to kill all forms of bacteria, regardless of their resistance profile or if they are Gram -ve or +ve or even if they are protected within biofilm, it has become widely adopted as an alternative to antibiotic therapy specifically in cases where patients are at a severe stage of infection such as those associated to diabetic foot ulcers and left ventricular assist device infections.

 

It has been praised as a life-saving medical device helping to heal infections that have been stalled for a very long time where conventional therapies have failed to act, reduce amputation and mortality rates.

This year we look forward to releasing a series of Health Economic publications documenting the cost effectiveness of our medical device against the use conventional therapies. We look forward to releasing this information to you in due time.

 

Until then, please reach out to us to learn more about why the interest in our medical device is growing daily. The data collection of our safety and efficacy shows why using an Adtec SteriPlas could completely change the way you treat patients.


Characterisation of a Cold Atmospheric Pressure Plasma Torch for Medical Applications

 

We congratulate Dr Adam Bennett on his most recent publication, “Characterisation of a Cold Atmospheric Pressure Plasma Torch for Medical Applications: Demonstration of Device Safety”.

 

The safety and effectiveness of plasma devices are of crucial importance, especially for applications where the plasma is discharged near humans. This study presents the novel design and characterisation of a Cold Atmospheric Plasma torch (SteriPlas), which is used in medical applications. The study shows the characterisation methodology that must be undertaken to show that a plasma device is safe, especially when used in an application on human skin. The emission spectrum discharged from the plasma torch is shown. The UV emitted is measured and the effective irradiance is calculated. The effective irradiance enables the determination of the maximum UV exposure limits, which in this application are shown to be over two hours; however, in some applications may be only seconds. NOx and ozone emissions are also recorded. The NOx levels in this application are shown to be orders of magnitude lower than their safety limits and the ozone emissions are also shown to be safe; however, in some plasma technologies the NOx and ozone levels are orders of magnitude higher than the safe levels.

 

This paper concludes with a discussion of how safety limits vary in different regions around the world and proposes an international standard. It documents the safety of our medical device which further reiterates one of our main strengths where no side effects have been reported.

 

Access to the full paper can be found here: https://www.mdpi.com/2076-3417/11/24/11864


E-poster at the EADV 2021 Conference

 

We look forward to supporting Fiona Koch’s e-poster that will be live during the EADV 2021 Spring Symposium tomorrow. Tune in to their website to get full access to her poster, “Efficacy of cold atmospheric plasma versus diclophenac 3% gel in patients with actinic keratoses: a prospective, randomized and rater-blinded study (ACTICAP)”.

 

To learn more about the Adtec SteriPlas’ strong clinical efficacy for the treatment of actinic keratoses, contact us at info@adtecplasma.com


The SteriPlas sets foot in the U.S.A.

We are excited to share news of our collaboration with The Southern Illinois University in United States of America. Our Adtec SteriPlas will be used as part of their study to examine the effect of cold plasma on a variety of infection burn model cases in a research laboratory setting. This study aims to help tackle the outbreaks of antimicrobial resistant microorganisms that continues to be an issue for burns cases. We look forward to providing more information and the results as the study progresses.


Plastische Chirurgie features the Adtec SteriPlas

Be sure to read our latest advertorial in the Plastische Chirurgie magazine featuring the Adtec SteriPlas for the treatment of actinic keratoses. Our medical device has been thoroughly tested in clinical trials and studies to prove its efficacy for the treatment of complex and impaired wounds, surgical site infections and medical dermatology conditions leading to accelerated healing.

 

Existing conventional therapies currently on the market for actinic keratoses have sometimes been shown to bear undesirable side effects. So we are proud to boast the safety and reliability of the Adtec SteriPlas with no side effects reported over continuing use since its existence especially for the treatment of actinic keratoses lesions.

 

To learn more about our medical device, send us an email at info@adtecplasma.com